Alpine Immune Sciences Inc (ALPN)

NASDAQ
Currency in USD
64.970
0.000(0.00%)
Closed·
Showing Alpine Immune Sciences historical data. For real-time data please try another search
Fair Value
Day's Range
64.97065.000
52 wk Range
34.25065.000
Key Statistics
Edit
Prev. Close
64.97
Open
64.98
Day's Range
64.97-65
52 wk Range
34.25-65
Volume
-
Average Volume (3m)
2.45M
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALPN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Alpine Immune Sciences Inc News & Analysis

Show more

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company’s product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. As of May 20, 2024, Alpine Immune Sciences, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated.

Alpine Immune Sciences Inc SWOT Analysis


Vertex's Bold Move
Explore Vertex's $4.9 billion acquisition of Alpine Immune Sciences, offering a 67% premium and reshaping the autoimmune disease treatment landscape
Povetacicept Promise
Delve into Alpine's lead candidate povetacicept, its potential best-in-class profile for IgAN, and its expansion into other autoimmune indications
Pipeline Progress
Learn about Alpine's upcoming clinical milestones, including the RAINIER Phase III trial and DENALI Phase II study, set to commence in late 2024
Market Valuation
Analysts set a $65 price target, reflecting the acquisition price and strong confidence in Alpine's pipeline and future potential in autoimmune therapies
Read full SWOT analysis

Earnings

Latest Release
Aug 13, 2024
EPS / Forecast
-- / -0.444
Revenue / Forecast
-- / 2.99M
EPS Revisions
Last 90 days

ALPN Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.